TG Therapeutics reports $228M Q2 BRIUMVI revenue, raises 2026 guidance to ~$950M

Filed August 3, 2026 · Period ending August 3, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 U.S. BRIUMVI revenue of $228M, up 64% year-over-year; company raised full-year 2026 total revenue guidance to ~$950M and U.S. BRIUMVI revenue to $890-905M, targeting ~$1B annualized exit run rate.

  Exhibit 99.1 view on EDGAR →
• high

  Phase 3 ENHANCE trial met primary endpoint, demonstrating bioequivalent exposure for single 600mg infusion versus current two-infusion initiation regimen, potentially simplifying treatment start.

  Exhibit 99.1 view on EDGAR →
• high

  Phase 1 subcutaneous BRIUMVI showed >60% bioavailability versus IV; fully enrolled Phase 3 trial evaluating quarterly subcutaneous dosing expects topline data year-end 2026 or early 2027.

  Exhibit 99.1 view on EDGAR →